BIOMARIN PHARMACEUTICAL INC
8-K December 22, 2025
Key Highlights
- BioMarin Pharmaceutical Inc. has stopped the development of BMN 349, an oral dru...
- This decision represents a significant setback, as it means a substantial invest...
- The discontinuation impacts patients by removing a potential new treatment optio...
Read Analysis
🤖 AI Generated